全文获取类型
收费全文 | 4017篇 |
免费 | 183篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 56篇 |
妇产科学 | 39篇 |
基础医学 | 385篇 |
口腔科学 | 177篇 |
临床医学 | 341篇 |
内科学 | 980篇 |
皮肤病学 | 252篇 |
神经病学 | 250篇 |
特种医学 | 142篇 |
外科学 | 510篇 |
综合类 | 10篇 |
一般理论 | 1篇 |
预防医学 | 138篇 |
眼科学 | 133篇 |
药学 | 350篇 |
中国医学 | 8篇 |
肿瘤学 | 416篇 |
出版年
2023年 | 23篇 |
2022年 | 60篇 |
2021年 | 100篇 |
2020年 | 79篇 |
2019年 | 78篇 |
2018年 | 106篇 |
2017年 | 74篇 |
2016年 | 103篇 |
2015年 | 93篇 |
2014年 | 163篇 |
2013年 | 188篇 |
2012年 | 290篇 |
2011年 | 266篇 |
2010年 | 154篇 |
2009年 | 124篇 |
2008年 | 238篇 |
2007年 | 231篇 |
2006年 | 258篇 |
2005年 | 230篇 |
2004年 | 202篇 |
2003年 | 186篇 |
2002年 | 172篇 |
2001年 | 52篇 |
2000年 | 51篇 |
1999年 | 52篇 |
1998年 | 39篇 |
1997年 | 29篇 |
1996年 | 31篇 |
1995年 | 34篇 |
1994年 | 18篇 |
1993年 | 26篇 |
1992年 | 39篇 |
1991年 | 26篇 |
1990年 | 36篇 |
1989年 | 34篇 |
1988年 | 21篇 |
1987年 | 28篇 |
1986年 | 27篇 |
1985年 | 23篇 |
1984年 | 28篇 |
1983年 | 22篇 |
1982年 | 20篇 |
1981年 | 21篇 |
1980年 | 17篇 |
1979年 | 12篇 |
1978年 | 13篇 |
1977年 | 12篇 |
1973年 | 6篇 |
1972年 | 8篇 |
1970年 | 7篇 |
排序方式: 共有4217条查询结果,搜索用时 0 毫秒
91.
92.
93.
Elena Biagini Iacopo Olivotto Maria Iascone Maria I. Parodi Francesca Girolami Giulia Frisso Camillo Autore Giuseppe Limongelli Massimiliano Cecconi Barry J. Maron Martin S. Maron Stefania Rosmini Francesco Formisano Beatrice Musumeci Franco Cecchi Attilio Iacovoni Tammy S. Haas Maria L. Bacchi Reggiani Paolo Ferrazzi Francesco Salvatore Paolo Spirito Claudio Rapezzi 《The American journal of cardiology》2014
94.
95.
96.
Meira Maria Forcelini Machado Taysa Bervian Bassani Valentín Cóppola-Segovia Eric Luiz Rossa Moura Silvio Marques Zanata Roberto Andreatini Maria Aparecida Barbato Frazão Vital 《Pharmacological reports : PR》2019,71(4):556-564
BackgroundPeroxisome proliferator-activated receptor γ (PPAR-γ) agonists have received much attention in research because of their neuroprotective and anti-inflammatory effects that reduce cell death and halt the progression of neurodegeneration. Thus, this study observed the pioglitazone effects on the main inflammatory markers after 6-hydroxydopamine (6-OHDA) lesion.MethodsThe effects of a 5-day administration of the PPAR-γ agonist pioglitazone (30 mg/kg) in male Wistar rats that received bilateral intranigral infusions of 6-OHDA. After surgery, the rats were evaluated in the open-field test on days 1,7,14, and 21. Immediately after the behavioral tests on day 21, the rats were euthanized, and the substantia nigra was removed to analyze the expression of nuclear factor κB (NF-κB) and IκB by western blot. To immunohistochemical, animals were intracardially perfused, with brain removal that was frozen and sectioned, being selected slices of the SNc region to detect tyrosine hydroxylase (TH) immunoreactivity, microglia activation (Iba-1) and NF-κB translocation in the nucleus.ResultsPioglitazone protected rats against hypolocomotion and 6-OHDA-induced dopaminergic neurodegeneration on day 7. Decreases in the microglial activation and the NF-κB expression were observed, and the p65 activation was inhibited.ConclusionsThese results suggest that pioglitazone may be a potential adjuvant for the treatment of Parkinson`s disease because of its effects on pathological markers of the progression of neurodegeneration. 相似文献
97.
98.
99.
Borrelli S De Nicola L Minutolo R Sagliocca A Garofalo C Liberti ME Pacilio M Iorio V Michini C Pirro L Conte G 《Giornale italiano di nefrologia》2012,29(4):418-424
International guidelines recommend to reduce blood pressure (BP) levels below 130/80 mmHg in non-dialysis chronic kidney disease (CKD) patients. However, this BP target has not been validated by randomized controlled trials and is mainly driven by data obtained in observational and post-hoc analyses suggesting that it improves the renal and, to some extent, cardiovascular prognosis. The inconclusive results on the prognostic role of the BP target in patients with CKD might also relate to the limited ability of office BP readings to adequately stratify the global risk of this population. In fact, alterations of the pressure profile (such as white-coat hypertension) and nighttime hypertension are common in CKD patients. Recent studies have demonstrated that ambulatory blood pressure monitoring (ABPM) is superior to clinic BP measurements in predicting renal death and cardiovascular events. Therefore, while waiting for the results from the ongoing randomized Systolic Blood Pressure Intervention Trial (SPRINT) comparing the effect on cardiorenal prognosis of two BP target levels, the more widespread use of ABPM is desirable in CKD patients. 相似文献
100.